Malignant Melanoma: Staging and Treatment of Localized and Advanced Disease

Morton DL , Wen DR , Wong JH , et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 1992;127:392–399.

Reintgen DS , Cruse CW , Berman C , et al. The orderly progression of melanoma nodal metastases. Arch Surg. 1994;220:759–767.

Norman J , Cruse CW , Espinosa C , et al. Redefinition of cutaneous lymphatic drainage with the use of lymphoscintigraphy for malignant melanoma. Am J Surg. 1991;162:432–437.

Wang X , Heller R , VanVoorhis N , et al. Detection of submicroscopic lymph node metastases with polymerase chain reaction in patients with malignant melanoma. Ann Surg. 1994;220:768–774.

Dale P , Wang Y , Conrad A , et al. Multiple marker polymerase chain reaction assay for evaluating circulating melanoma cells. Proc Annu Meet Am Soc Clin Oncol. 1995;14:A413. Abstract.

Shivers SC , Wang X , Li W , et al. Molecular staging of malignant melanoma: correlation with clinical outcome. JAMA. 1998;280:1410–1415.

Buzaid A.C. , Ross M.I. , Balch C.M. . Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system. J Clin Oncol. 1997; 15: 1039–1051.

Agarwala S.S. , Kirkwood J.M. . Adjuvant interferon treatment for melanoma. Hematol Oncol Clin North Am. 1998; 12: 823–833.

Kirkwood J.M. , Strawderman M.H. , Ernstoff M.S. . Adjuvant therapy of high-risk melanoma: the role of high-dose interferon alfa-2b. In: Salmon S.E. , ed. Adjuvant Therapy of Cancer, VIII: Proceedings of the Eighth International Conference on the Adjuvant Therapy of Cancer, Scottsdale, Arizona, March, 1996. Philadelphia, Pa: Lippincott-Raven Publishers; 1997: 251–257.

Kirkwood J.M. , Strawderman M.H. , Ernstoff M.S. . Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 1996; 14: 7–17.

Cole B.F. , Gelber R.D. , Kirkwood J.M. . A quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment for high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group Study. J Clin Oncol. 1996; 14: 2666–2673.

Hillner B.E. , Kirkwood J.M. , Atkins M.B. . Economic analysis of adjuvant interferon alfa-2b in high-risk melanoma based on projections from Eastern Cooperative Oncology Group 1684. J Clin Oncol. 1997; 15: 2351–2358.

Creagan E.T. , Dalton R.J. , Ahmann D.L. . Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma. J Clin Oncol. 1995; 13: 2776–2783.

Cascinelli N. , Bufalino R. , Morabito A. . Results of adjuvant interferon study in WHO melanoma programme. Lancet. 1994; 343: 913–914.

Cascinelli N. . Evaluation of efficacy of adjuvant rIFNa2a in melanoma patients with regional node metastases. Proc Annu Meet Am Soc Clin Oncol. 1995; 14: A1296. Abstract.

Grob J.J. , Dreno B. , Delaunay M. . Long term results of an adjuvant therapy with low doses IFN-alpha2A in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. Melanoma Res. 1997; 7: S33. Abstract.

Jones P.C. , Sze L.L. , Liu P.Y. . Prolonged survival for melanoma patients with elevated IgM antibody to oncofetal antigen. J Natl Cancer Inst. 1981; 66: 249–254.

Livingston P.O. , Wong G.Y. , Adluri S. . Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol. 1994; 12: 1036–1044.

Livingston P.O. . The case for melanoma vaccines that induce antibodies. In: Kirkwood J.M. , ed. Molecular Diagnosis and Treatment of Melanoma. New York, NY: M Dekker; 1998.